Loading clinical trials...
Loading clinical trials...
The purpose of this study is to assess safety and efficacy of brentuximab vedotin in combination with bendamustine in patients with relapsed or refractory Hodgkin lymphoma. It is an open-label, 2-stag...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Seagen Inc.
NCT02682667 · Multiple Myeloma, Lymphoma, Non-Hodgkin, and more
NCT01676805 · Hodgkin Disease, Lymphoma, Non-Hodgkin, and more
NCT07283822 · Non-Hodgkin Lymphoma, Hodgkin Disease Lymphoma, and more
NCT07209059 · Hodgkin Lymphoma, Hodgkin Disease, and more
NCT02287311 · Hodgkin Disease, Non-Hodgkin Lymphoma, and more
University of Alabama at Birmingham
Birmingham, Alabama
Pacific Hematology Oncology Associates
San Francisco, California
Stanford Cancer Center
Stanford, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions